Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Biofluid Biopsies
Conferences  \  Biofluid Biopsies and Companion Diagnostics 2014  \  Biofluid Biopsies  \  Agenda  \  Nicholas Dracopoli
RegisterLogin

Nicholas Dracopoli's Biography


Nicholas Dracopoli, Vice President/Head, Johnson & Johnson

Dr. Nicholas Dracopoli is Vice President, Head Oncology Biomarkers at Janssen R&D, Johnson & Johnson. In this role he is responsible for biomarker discovery, development and applications for oncology products. Previously, he was Vice President of Clinical Discovery Technologies at Bristol-Myers Squibb, and prior to that spent five years in the biotechnology industry at Sequana Therapeutics. Dr Dracopoli obtained his B.Sc. and Ph.D. degrees from the University of London, and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center and the Massachusetts Institute of Technology (MIT). Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center, and as a Section Chief at the National Center for Human Genome Research at the NIH before moving to the biotechnology industry. Dr Dracopoli has authored >70 scientific publications, and has extensive experience in the fields of genomics, molecular biology and cancer research.

Nicholas Dracopoli Image

Circulating Tumor Cells (CTCs): From Enumeration to Comprehensive Characterization

Tuesday, 28 October 2014 at 09:00

Add to Calendar ▼2014-10-28 09:00:002014-10-28 10:00:00Europe/LondonCirculating Tumor Cells (CTCs): From Enumeration to Comprehensive CharacterizationSELECTBIOenquiries@selectbiosciences.com

Inexpensive, minimally-invasive Dx tests that can be used repeatedly throughout the course of disease are critically important for the effective development of targeted therapies in Oncology. Circulating Tumor Cells (CTC) are the only tumor cells that can be accessed in a cancer patient without requiring an invasive procedure. Current FDA approved uses for CTCs are limited to monitoring response to therapy and prognosis in patients with metastatic breast, prostate or colorectal cancer by enumerating the total number of CTCs. However, the development of more sensitive and specific methods to capture diverse types of CTCs (epithelial and non epithelial cancers, cancer stem cells, cells undergoing epithelial-mesenchymal transition etc.), and more sensitive analytical methods using much small amounts of nucleic acid or protein templates are both required to enable the comprehensive molecular analysis of CTCS. These data can be used to direct therapy using real-time Dx analyses of the driver mutations and emergent drug resistance in metastatic cancer patients, and provide a new opportunity to improve the outcome of patients with cancer.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid BiopsiesSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors